Fragile X syndrome - insight into what we know and prospects
DOI:
https://doi.org/10.12775/JEHS.2023.19.01.006Keywords
Fragile X syndrome, autism, neurodevelopmental disorders, FMRP, FMR1Abstract
Fragile X syndrome is a dominantly inherited genetic disease and is a consequence of the FMR1 gene mutation located on the X chromosome. The number of patients affected by this disease with full mutation is estimated at 1 in 4000 men and 1 in 8000 women, however, the number of carriers with premutation is far greater. Depending on the mutation of the FMR1 gene and levels of its products FMRP a variety of symptoms can be observed including- intellectual disability, mental retardation, lowered behavioral adaptation, autism, and dysmorphic features such as a long face with a broad forehead and prominent ears. The treatment is mostly symptomatic- managing comorbidities and an emphasis on psychological therapy. The objective of this paper is to sum up the most up-to-date knowledge regarding the pathogenesis, treatment- current and clinically tested, and novelties in the Fragile X syndrome
References
Kniffin CL. # 300624 FRAGILE X SYNDROME; FXS. https://www.omim.org/entry/309000. (accessed: 2022.12.05).
Rajaratnam A, Shergill J, Salcedo-Arellano M, Saldarriaga W, Duan X, Hagerman R. Fragile X syndrome and fragile X-associated disorders. F1000Res. 2017;6:2112. https://doi.org/10.12688/f1000research.11885.1
Ciaccio C, Fontana L, Milani D, Tabano S, Miozzo M, Esposito S. Fragile X syndrome: a review of clinical and molecular diagnoses. Ital J Pediatr. 2017;43(1):39. https://doi.org/10.1186/s13052-017-0355-y
Salcedo-Arellano MJ, Dufour B, McLennan Y, Martinez-Cerdeno V, Hagerman R. Fragile X syndrome and associated disorders: Clinical aspects and pathology. Neurobiol Dis. 2020;136:104740. https://doi.org/10.1016/j.nbd.2020.104740
Niu M, Han Y, Dy ABC, Du J, Jin H, Qin J, et al. Fragile X Syndrome: Prevalence, Treatment, and Prevention in China. Front Neurol. 2017;8:254. https://doi.org/10.3389/fneur.2017.00254
Zafarullah M, Tassone F. Molecular Biomarkers in Fragile X Syndrome. Brain Sci. 2019;9(5):96. https://doi.org/10.3390/brainsci9050096
“What is Fragile X Syndrome (FXS)? | CDC.” https://www.cdc.gov/ncbddd/fxs/facts.html (accessed: 2022.12.06).
Richter JD, Zhao X. The molecular biology of FMRP: new insights into fragile X syndrome. Nat Rev Neurosci. 2021;22(4):209-222. https://doi.org/10.1038/s41583-021-00432-0
Bagni C, Zukin RS. A Synaptic Perspective of Fragile X Syndrome and Autism Spectrum Disorders. Neuron. 2019;101(6):1070-1088. https://doi.org/10.1016/j.neuron.2019.02.041
Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB Jr, Moine H, Kooy RF, et al. Fragile X syndrome. Nat Rev Dis Primers. 2017;3:17065. https://doi.org/10.1038/nrdp.2017.65
Landowska A., Rzońca S., Bal J., Gos M.. Zespół łamliwego chromosomu x i choroby FMR1-zależne - Objawy kliniczne, epidemiologia i podłoże molekularne choroby. [Fragile X syndrome and FMR1-dependent diseases - clinical presentation, epidemiology and molecular background]. Journal of Mother and Child. 2018;22(1):14-21. Polish https://doi.org/10.34763/devperiodmed.20182201.1421
Gómez-Rodríguez MJ, Morales-Conejo M, Arteche-López A, Sánchez-Calvín MT, Quesada-Espinosa JF, Gómez-Manjón I, et al. Fragile X Syndrome Caused by Maternal Somatic Mosaicism of FMR1 Gene: Case Report and Literature Review. Genes (Basel). 2022;13(9):1609. https://doi.org/10.3390/genes13091609
Vafaeie F, Alerasool M, Kaseb Mojaver N, Mojarrad M. Fragile X Syndrome in a Female With Homozygous Full-Mutation Alleles of the FMR1 Gene. Cureus. 2021;13(7):e16340. https://doi.org/10.7759/cureus.16340
Castagnola S, Bardoni B, Maurin T. The Search for an Effective Therapy to Treat Fragile X Syndrome: Dream or Reality?. Front Synaptic Neurosci. 2017;9:15. https://doi.org/10.3389/fnsyn.2017.0001
D'Incal C, Broos J, Torfs T, Kooy RF, Vanden Berghe W. Towards Kinase Inhibitor Therapies for Fragile X Syndrome: Tweaking Twists in the Autism Spectrum Kinase Signaling Network. Cells. 2022;11(8):1325. https://doi.org/10.3390/cells11081325
Coleman J, Riley K. Fragile X Syndrome. Encyclopedia of Infant and Early Childhood Development. Elesevier;2022
Rais M, Binder DK, Razak KA, Ethell IM. Sensory Processing Phenotypes in Fragile X Syndrome. ASN Neuro. 2018;10:1759091418801092. https://doi.org/10.1177/1759091418801092
Raspa M, Wheeler AC, Riley C. Public Health Literature Review of Fragile X Syndrome. Pediatrics. 2017;139(3):153-171. https://doi.org/10.1542/peds.2016-1159C
Tartaglia N, Bonn-Miller M, Hagerman R. Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature. Cannabis Cannabinoid Res. 2019;4(1):3-9. https://doi.org/10.1089/can.2018.0053
Sodhi DK, Hagerman R. Fragile X Premutation: Medications, Therapy and Lifestyle Advice. Pharmgenomics Pers Med. 2021;14:1689-1699. https://doi.org/10.2147/PGPM.S338846
Dy ABC, Tassone F, Eldeeb M, Salcedo-Arellano MJ, Tartaglia N, Hagerman R. Metformin as targeted treatment in fragile X syndrome. Clin Genet. 2018;93(2):216-222. https://doi.org/10.1111/cge.13039
Berry-Kravis E, Hagerman R, Visootsak J, et al. Arbaclofen in fragile X syndrome: results of phase 3 trials. J Neurodev Disord. 2017;9:3. https://doi.org/10.1186/s11689-016-9181-6
Heussler H, Cohen J, Silove N, Tich N, Bonn-Miller MO, Du W, et al. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. J Neurodev Disord. 2019;11(1):16. https://doi.org/10.1186/s11689-019-9277-x
Monyak RE, Emerson D, Schoenfeld BP, Zheng X, Chambers DB, Rosenfelt C, et al. Insulin signaling misregulation underlies circadian and cognitive deficits in a Drosophila fragile X model. Mol Psychiatry. 2017;22(8):1140-1148. https://doi.org/10.1038/mp.2016.51
Berry-Kravis E, Horrigan JP, Tartaglia N, Hagerman R, Kolevzon A, Erickson CA, et al. A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome. Pediatr Neurol. 2020;110:30-41.
Hampson DR, Hooper AWM, Niibori Y. The Application of Adeno-Associated Viral Vector Gene Therapy to the Treatment of Fragile X Syndrome. Brain Sci. 2019;9(2):32. https://doi.org/10.3390/brainsci9020032
Okoniewski KC, Wheeler AC, Lee S, Boyea B, Raspa M, Taylor JL, et al. Early Identification of Fragile X Syndrome through Expanded Newborn Screening. Brain Sci. 2019;9(1):4. https://doi.org/10.3390/brainsci9010004
“Early Check - Home.” https://www.earlycheck.org/ (accessed: 2022.12.13).
Hayward BE, Kumari D, Usdin K. Recent advances in assays for the fragile X-related disorders. Hum Genet. 2017;136(10):1313-1327. https://doi.org/10.1007/s00439-017-1840-5
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Adam Strzoda, Magdalena Kamińska, Anna Strzoda, Agata Strzoda, Wojciech Sowiński, Michał Zdybel, Agata Juda, Kornelia Rojek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 485
Number of citations: 0
